



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PPI-GIT1/ β -Pix interaction-IN-1

Cat. No.:	HY-152095		
CAS No.:	2070916-70-8		
Molecular Formula:	C ₂₃ H ₂₁ NO ₅		
Molecular Weight:	391.42		
Target:	Ras		
Pathway:	GPCR/G Protein; MAPK/ERK Pathway		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (255.48 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.5548 mL	12.7740 mL	25.5480 mL
		5 mM	0.5110 mL	2.5548 mL	5.1096 mL
10 mM		0.2555 mL	1.2774 mL	2.5548 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.5 mg/mL (6.39 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	PPI-GIT1/ β -Pix interaction-IN-1 is a potent and orally active GIT1/ β -Pix protein-protein interaction (PPI) inhibitor with a K_D value of 7.7 μ M. PPI-GIT1/ β -Pix interaction-IN-1 disrupts the GIT/PIX interaction can impact the activation of the downstream Rho GTPase Rac1 and Cdc42. PPI-GIT1/ β -Pix interaction-IN-1 inhibits metastasis of gastric cancer ^[1] .
In Vitro	PPI-GIT1/ β -Pix interaction-IN-1 (compound 14-5-18; 0-50 μ M) inhibits the interaction between GIT1 and β -Pix in living cells ^[1] . PPI-GIT1/ β -Pix interaction-IN-1 (0-50 μ M; 24 h; MGC803 cells and MKN45 cells) inhibits gastric cancer cell invasion in a dose-dependent manner and disrupts the GIT/PIX interaction can impact the activation of the downstream Rho GTPase Rac1 and Cdc42 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]

	<table border="1"> <tr> <td>Cell Line:</td> <td>MGC803 cells and MKN45 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 20, and 50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Suppressed the expression of GTP-Rac1 and GTP-Cdc42 in a dose-dependent manner.</td> </tr> </table>	Cell Line:	MGC803 cells and MKN45 cells	Concentration:	0, 5, 20, and 50 μ M	Incubation Time:	24 hours	Result:	Suppressed the expression of GTP-Rac1 and GTP-Cdc42 in a dose-dependent manner.
Cell Line:	MGC803 cells and MKN45 cells								
Concentration:	0, 5, 20, and 50 μ M								
Incubation Time:	24 hours								
Result:	Suppressed the expression of GTP-Rac1 and GTP-Cdc42 in a dose-dependent manner.								
In Vivo	<p>PPI-GIT1/β-Pix interaction-IN-1 (compound 14-5-18; 10 and 30 mg/kg; i.g.; 24 h) inhibits gastric cancer cell invasion in female nude mice with MGC803 xenografts^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female nude mice with MGC803 xenografts (Four-week-old)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 and 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>oral gavage, daily, for 18 days</td> </tr> <tr> <td>Result:</td> <td>Reduced the luminescence intensity in the lungs in a dose-dependent manner.</td> </tr> </table>	Animal Model:	Female nude mice with MGC803 xenografts (Four-week-old) ^[1]	Dosage:	10 and 30 mg/kg	Administration:	oral gavage, daily, for 18 days	Result:	Reduced the luminescence intensity in the lungs in a dose-dependent manner.
Animal Model:	Female nude mice with MGC803 xenografts (Four-week-old) ^[1]								
Dosage:	10 and 30 mg/kg								
Administration:	oral gavage, daily, for 18 days								
Result:	Reduced the luminescence intensity in the lungs in a dose-dependent manner.								

REFERENCES

[1]. Gu J, et, al. Construction of a synthetic methodology-based library and its application in identifying a GIT/PIX protein-protein interaction inhibitor. Nat Commun. 2022 Nov 23;13(1):7176.

[2]. Gu J, et, al. Construction of a synthetic methodology-based library and its application in identifying a GIT/PIX protein-protein interaction inhibitor. Nat Commun. 2022 Nov 23;13(1):7176.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA